Strong order book masks margin compression amid transformation

Order backlog ₹2,289 Cr confirmed; +20% YoY verified; order intake ₹1,007 Cr flat YoY

Backlog composition shifted from 30% multi-year (Q1 FY26) to near-term 10–12 month projects; execution certainty improved but not quantified

PAT ₹22.1 Cr vs ₹10.1 Cr (Q1 FY26) = 117.7% growth; low absolute level (2.4% margin) masks weak profitability

EBITDA ₹94 Cr Q1 FY27 vs ₹75 Cr estimated Q4 FY26 ≈ +25% QoQ accurate; but EBITDA down 7% YoY despite +16% revenue growth signals margin compression

CRT +10% YoY, PPT +23% YoY, peptide orders cited but no standalone quantification; largely anecdotal without end-market volumes

Restructuring in place; no synergies quantified; margins compressed YoY; timing vague ('few quarters')

Four global divisions (CRT, PPT, HET, PST) replace India/International split. Expected to unlock 15% EBITDA margin via synergies and cross-selling; early execution signals mixed (margins down YoY).

Q1 FY26 had 30% multi-year projects; Q1 FY27 mostly 10–12 month cycles. Improves revenue visibility but may not support higher margins.

Significant CDMO investment in India (Hyderabad), US onshoring (Trump policy), China rebound reported. Last quarter pharma was 'tough'; now 'green shoots' visible.

15% EBITDA margin reaffirmed as aspiration. No change to target, only timeline pushed (will take 'few quarters', full stabilization 18–24 months).

Pharma strong in India (CDMO, Hyderabad players expanding); US pharma picking up; China returned with orders; Europe still slow. Chemicals flat in India, challenging in Europe. Management cautiously optimistic on pharma, bearish on chemicals.

HET growth (lower margin, large projects) diluting blended margin. Organizational investment ongoing. Cost improvement program in progress; expect recovery with volume and pricing power.

All divisions around 15% EBITDA aspiration. Some units significantly higher, 1–3 units underperforming. No specific divisional margin targets disclosed. Tracking ongoing.

Multiple initiatives underway. No specific cadence. Will build consistency over 'few quarters', then discuss. Analyst pressed; management deferred.

New org structure enables faster global decision-making, cross-selling, shared knowledge. Management focused on organizational narrative rather than specific sales metrics.

No specific targets for FY27/28. General expectation of QoQ margin tracking; 15% is 'aspiration'. No cadence provided.

Large majority (significant portion of ₹1,007 Cr Q1 intake). Roughly 10–12 month execution cycles for most projects. Contrasts Q1 FY26 (30% multi-year).

EUR 7 million repayment by Q2. Further restructuring over 12–18 months. No specific end-year target disclosed. CFO: 'will not mention debt target for end of year'. Analyst frustrated.

Target ~30%, maybe slightly lower. Takes 18–24 months to stabilize via org/debt structure changes. FY27–28 will remain elevated.

Pharma green shoots look structural (India CDMO, US onshoring, China returning, peptide boom). CRT saw strong orders in US, China, large orders in Europe despite weakness. PPT driven by Brazil mixing, India pharma. Cautiously optimistic but noted execution variability.

Intent to bring down employee costs over time. Some new hires necessary for global structure (HR, finance, IT). Plan to shift non-critical work to India (GEC, GCC model). Cost optimization ongoing (UK, Germany already cut headcount).

Interest 6–7% (hedged). Order intake profile very different this year (10–12 month vs 30% multi-year last year). Strong revenue visibility from current backlog if market sustains.

Delivered +16.4% YoY in Q1. Order backlog ₹2,289 Cr mostly 10–12 month execution supports FY27 upside if backlog converts.

Q1 delivered 10.1%; management cited cost investments, complex structure, financing drag. Timeline 'few quarters' to show consistency; full stabilization 18–24 months.

Management focused on working capital optimization, debt reduction, and cost rationalization. No indication of major capex plans.

EBITDA margin 10.1% vs 15% target; YoY decline 7% despite 16% revenue growth. Organizational restructuring costs frontloaded; payoff uncertain. Multiple 'underperforming units' drag group margins.

PAT ₹22 Cr on EBITDA ₹94 Cr (24% flow-through). Financing costs (6–7% interest), complex multi-entity tax structure, overlapping administrative overhead limit cash generation. Tax rate currently high; targeting ~30% in 18–24 months.

Order backlog ₹2,289 Cr provides revenue visibility, but shift to 10–12 month cycles (vs 30% multi-year prior year) means execution pressure higher. Quality and margin of orders not disclosed. Pharma green shoots may be cyclical, not structural.

₹835 Cr gross debt; EUR 7 million (~₹65 Cr) repayment by Q2. No specific end-year or FY28 target. Refinancing strategy under development. Leverage metrics not improving yet. CFO deferred debt target commitment.

Chemical sector remains 'flat' in India and 'challenging' in Europe. CRT and PPT exposure to chemicals noted. Recovery timeline unclear. Pharma strength may not offset chemical headwind.